
Sign up to save your podcasts
Or


In this company introduction, we speak with David Elsley, President & CEO of Cardiol Therapeutics (NASDAQ/TSX: CRDL), a clinical-stage life sciences company focused on developing therapies to address inflammation-driven cardiovascular diseases.
Cardiol’s lead asset, CardiolRx™, is currently in:
We also cover:
Please email me any further questions you have for David. My email address is [email protected].
Click here to learn more about Cardiol Therapeutics.
By KE Report4.3
1212 ratings
In this company introduction, we speak with David Elsley, President & CEO of Cardiol Therapeutics (NASDAQ/TSX: CRDL), a clinical-stage life sciences company focused on developing therapies to address inflammation-driven cardiovascular diseases.
Cardiol’s lead asset, CardiolRx™, is currently in:
We also cover:
Please email me any further questions you have for David. My email address is [email protected].
Click here to learn more about Cardiol Therapeutics.

3,072 Listeners

147 Listeners

147 Listeners

97 Listeners

361 Listeners

268 Listeners

95 Listeners

76 Listeners

372 Listeners

71 Listeners

417 Listeners

86 Listeners

44 Listeners

23 Listeners

155 Listeners